Atorvastatin: A Drusen Disintegrator?Atorvastatin: A Drusen Disintegrator?
Can treatment with a high-dose statin for age-related macular degeneration resolve drusen and improve visual acuity? Medscape Optometry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2016 Category: Consumer Health News Tags: Viewpoint Source Type: news

Studying for USMLE Step 2? Master this most missed question
Studying for the United States Medical Licensing Examination® (USMLE®) Step 2 may seem daunting, but not to fear. Starting this month, we’re giving you an exclusive scoop on the most missed USMLE Step 2 test prep questions and expert strategies to help you beat them. Check out this month’s most challenging question, and view an expert video explanation of the answer from Kaplan Medical. Welcome to the first Step 2 post in AMA Wire’s® series, “Tutor talk: Tips from Kaplan Medical on the most missed USMLE test prep questions from Kaplan’s Qbank.” Each month, we’re revealing the top questions students miss...
Source: AMA Wire - February 24, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news

Could statins treat common cause of vision loss?
ConclusionThe difference between the dramatic improvement seen in the case study of the 63-year-old man and the comparatively modest, or lack of, effect seen in the 23 taking part in the trial shows the limitations of studying small numbers of people, and the current uncertainly about the effects of this treatment. There is large variability in small groups, which doesn't tell us whether the treatment will help most people. The way to solve this is to study lots more people. This helps to smooth out the natural variability in people's responses to the same treatment and can highlight groups more or less likely to benefit. ...
Source: NHS News Feed - February 5, 2016 Category: Consumer Health News Tags: Older people Medication Source Type: news

STATINS found to clear away deposits that cause blindness in the elderly
High-dose treatment with the statin Lipitor cleared away fatty deposits behind the retina, leading to visual improvement in patients with age-related macular degeneration (AMD), say Harvard researchers. (Source: the Mail online | Health)
Source: the Mail online | Health - February 5, 2016 Category: Consumer Health News Source Type: news

The Jekyll and Hyde of Statins
By Drs. David Niesel and Norbert Herzog, Medical Discovery News Cholesterol-lowering drugs called statins are the most prescribed drug ever. About 30 percent of Americans are currently taking statins such as Crestor, Lipitor, Mevacor and Zocor. Overall, statins can be good thing, but as with all drugs, there are some negative effects. Statins lower cholesterol by inhibiting a protein called HMG-CoA reductase. Since high cholesterol levels are linked to heart disease, statins can reduce the risks of heart attack and stroke, two of the leading causes of death in the United States. Recent reports from the American Heart Ass...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news

Identifying Acute STEMI in the Presence of Paced Rhythm
EMS responds to a local coffee shop for a 77-year-old male who has reportedly fainted. While en route the call is upgraded to an unconscious patient and an engine company is dispatched for backup. On arrival the patient is conscious but lethargic. He appears acutely ill. The skin is pale and diaphoretic. His past medical history includes hypertension, dyslipidemia, myocardial infarction, a coronary artery bypass graft and heart failure. His current medications are aspirin, metoprolol, atorvastatin, lisinopril and furosemide. Upon further questioning he admits to chest discomfort. His OPQRST assessment is as follows: ≫ On...
Source: JEMS Patient Care - January 18, 2016 Category: Emergency Medicine Authors: Tom Bouthillet, NREMT-P Tags: Case of the Month Special Topics Cardiac & Resuscitation Patient Care Source Type: news

Identifying Acute STEMI in the Presence of Paced Rhythm
EMS responds to a local coffee shop for a 77-year-old male who has reportedly fainted. While en route the call is upgraded to an unconscious patient and an engine company is dispatched for backup. On arrival the patient is conscious but lethargic. He appears acutely ill. The skin is pale and diaphoretic. His past medical history includes hypertension, dyslipidemia, myocardial infarction, a coronary artery bypass graft and heart failure. His current medications are aspirin, metoprolol, atorvastatin, lisinopril and furosemide. Upon further questioning he admits to chest discomfort. His OPQRST assessment is as follows: ≫ On...
Source: JEMS Special Topics - January 18, 2016 Category: Emergency Medicine Authors: Tom Bouthillet, NREMT-P Tags: Case of the Month Special Topics Cardiac & Resuscitation Patient Care Source Type: news

The Biggest Medical Stories You May Have Missed In 2015
SPECIAL FROM Next Avenue By Craig Bowron As we head into the New Year, let’s take a look back and see what lessons we should have learned from medical science in 2015. The New England Journal of Medicine’s publication Journal Watch provides physicians and other health care providers with expert analysis of the most recent medical research. Below is a brief synopsis of what the Journal Watch editors felt were the most important stories in general medicine for the year 2015. While you likely heard about a couple, others probably escaped your radar. Getting Aggressive with Strokes We’re familiar with the...
Source: Science - The Huffington Post - January 15, 2016 Category: Science Source Type: news

Brent Saunders Softens His View On Research With Jim Cramer On 'Mad Money'
Drug discovery is a key component of R&D and Pfizer has a long history of discovering major new medicines, including drugs like Zoloft, Zithromax, Lipitor and, yes, Viagra. However, Saunders has made his reputation on repudiating the need for such investments. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 1, 2015 Category: Pharmaceuticals Authors: John LaMattina Source Type: news

Pfizer-Allergan deal a prelude to splitting company
(Reuters) — A Pfizer (NYSE:PFE) merger with Ireland-based Allergan (NYSE: AGN), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent. Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling 3 years of financial data treating its “established products” division, which sells generic medicines, and its “innovative” patent-protected medicines unit, as if they were separate companies. Such a split would dramatically boost the compan...
Source: Mass Device - November 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Pharmaceuticals Allergan Inc. Pfizer Inc. Source Type: news

Heart Disease and Diabetes Trials Anticipated at Kidney WeekHeart Disease and Diabetes Trials Anticipated at Kidney Week
New data will be presented on empagliflozin in patients with diabetes, and results from trials of atorvastatin and kidney injury after cardiac surgery will be released. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 29, 2015 Category: Consumer Health News Tags: Nephrology News Source Type: news